BioMarin Pharmaceutical Stock Price - BMRN

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
BioMarin Pharmaceutical Inc BMRN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.25 -0.36% 68.26 69.03 68.11 68.35 68.51 14:36:52
Bid Price Ask Price Spread Spread % News
68.24 68.27 0.03 0.04% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,186 392,629 $ 68.58 $ 26,925,908 1,312,385 62.88 - 106.74
Last Trade Time Type Quantity Stock Price Currency
14:36:48 100 $ 68.26 USD

BioMarin Pharmaceutical Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 12.23B 179.46M $ -77.21M -0.44 -95.53 177.77M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 16.00 0.90%

more financials information »

BioMarin Pharmaceutical News

Loading Messages....

Latest BMRN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BMRN Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week64.9269.2564.6467.14141M3.345.14%
1 Month74.9377.10562.8868.32351M-6.67-8.90%
3 Months80.6181.7362.8872.53121M-12.35-15.32%
6 Months92.2692.808662.8878.70491M-24-26.01%
1 Year100.09106.7462.8884.77911M-31.83-31.80%
3 Years84.83106.7462.8888.04301M-16.57-19.53%
5 Years66.44151.7762.1293.51901M1.822.74%

BioMarin Pharmaceutical Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.